Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Tarja Mälkönen; Pauliina Nuutinen; Taru Hallinen; Erkki Soini; Riikka Nissinen; Christina Wennerström; Tapio Rantanen; Johanna H. Hagman; Rauno Harvima; Johanna Höök-Nikanne; Tiina Ilves; Päivi Lintu; Ken Malanin; Iina Soramäki; Kaisa Tasanen; Arja Teho; Katja Vähävihu; Sari Itälinna; Pekka Leinonen; Piia Sarajärvi; Laura Huilaja; Rafael Pasternack

doi:10.2340/actadv.v101.910

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerström, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia SarajärviLaura Huilaja, Rafael Pasternack

Research output: Contribution to journal › Article › Scientific › peer-review

14 Citations (Scopus)

92 Downloads (Pure)

Abstract

Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.

Original language	English
Article number	adv00631
Number of pages	5
Journal	Acta Dermato-Venereologica
Volume	102
Early online date	14 Dec 2021
DOIs	https://doi.org/10.2340/actadv.v101.910
Publication status	Published - 2022
Publication type	A1 Journal article-refereed

Funding

The authors thank Petri Mankinen and Carola Ekstedt for their expertise in study management and Tuomas Lundström for his expertise in data management. This study was supported by Janssen-Cilag Oy (Finland). Conflicts of interest: TM received honoraria from Abbvie, Bristol Meyers Squibb, Eli Lilly, JanssenCilag, Novartis, Pfizer, and UCB Pharma for consulting and/or speaking. PN received educational grants from Celgene, Novartis, Medac and Sanofi, and honoraria for consulting/speaking from Boehringer-Ingelheim, Celgene, Janssen-Cilag, Leo Pharma, Lilly, Novartis, Mylan, Orion, UCB Pharma. TH is a partner, employee and chairman of the board of ESiOR Oy, and reports grants and nonfinancial support from Janssen-Cilag to ESiOR Oy during the conduct of the study. ES is a partner, employee and CEO of ESiOR Oy, and reports grants and nonfinancial support from JanssenCilag Oy to ESiOR Oy during the conduct of the study. RN and CW are employees of Janssen-Cilag. TR has received educational grants from UCB, AbbVie, Janssen and Novartis; and honoraria from Abbvie, Janssen, Leo Pharma, Lilly, Novartis and UCB for consulting and/or speaking. JH-N has received educational grants from Abbvie, Janssen-Cilag, Leo Pharma and UCB; honoraria from Novartis and Orion Pharma for consulting and/or speaking. PLi has received honoraria from Amgen for consulting and educational grants from Abbvie, Jans-sen, Leo Pharma, Medac, Novartis, and Sanofi. IS has received educational grants from pharmaceutical companies (e.g. Janssen, Novartis, Abbvie, Takeda). KT has received educational grants form Sanofi Genzyme and honoraria from Abbvie, Novartis, Sanofi Genzyme, Janssen-Cilag and UCB Pharma for consulting and/or speaking. AT has received educational grants from Amgen, Leo Pharma, Novartis,Abbvie, Janssen, Eli Lilly, and UCB Pharma. KV has received educational grants from Janssen-Cilag and honoraria from Abbvie and Amgen for consulting and/or speaking. SI has received educational grants from Novartis, Janssen and Medac. P.S. has received educational grants from Celgene, Novartis, Abbvie and Sanofi. LH has received educational grants from Takeda, JanssenCilag, Novartis, AbbVie and LEO Pharma, honoraria from Sanofi Genzyme, Novartis, Abbvie and UCB Pharma for consulting and/ or speaking, and is an investigator for Abbvie. RP has received educational grants from AbbVie and Janssen; honoraria from AbbVie, BMS, Eli Lilly, Janssen, Novartis, Sanofi Genzyme and UCB for consulting and/or speaking; participated in clinical studies spon- sored by AbbVie, BMS, Novartis, Eli Lilly, Pfizer and Regeneron. RH, JH, TI, KM, and PLe have no conflicts of interest to declare. The authors thank Petri Mankinen and Carola Ekstedt for their expertise in study management and Tuomas Lundstr?m for his expertise in data management. This study was supported by Janssen-Cilag Oy (Finland). There are no tender mechanisms or binding guidelines that determine the order in which biologic therapies should be used. Instead, the Finnish dermatologists are free to choose the clinically most appropriate biologic therapy for their patients. Intravenous drugs are funded by the municipalities (from the hospital budget), whereas self-administered prescription drugs, including guselku-mab, are funded by the Social Security Institution of Finland. Currently, biologic therapies for PsO are reimbursed for patients with severe and difficulttotreat chronic PsO. Since guselkumab was the first IL23inhibitor on the market, it was most likely used in patients having failed other treatments. Despite this, the findings of this nationwide study support high treatment persistence and effectiveness of guselkumab for the treatment of PsO in the Finnish real-world setting.

Keywords

Guselkumab
Persistence
Psoriasis
Realworld
Treatment outcome

Publication forum classification

Publication forum level 2

ASJC Scopus subject areas

Dermatology

Access to Document

10.2340/actadv.v101.910Licence: CC BY-NC

910Final published version, 765 KBLicence: CC BY-NC

https://urn.fi/URN:NBN:fi:tuni-202201311719Licence: CC BY-NC

Cite this

Mälkönen, T., Nuutinen, P., Hallinen, T., Soini, E., Nissinen, R., Wennerström, C., Rantanen, T., Hagman, J. H., Harvima, R., Höök-Nikanne, J., Ilves, T., Lintu, P., Malanin, K., Soramäki, I., Tasanen, K., Teho, A., Vähävihu, K., Itälinna, S., Leinonen, P., ... Pasternack, R. (2022). Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Dermato-Venereologica, 102, Article adv00631. https://doi.org/10.2340/actadv.v101.910

@article{3218660839af4f12a7bba31e0779569a,

title = "Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis",

abstract = "Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.",

keywords = "Guselkumab, Persistence, Psoriasis, Realworld, Treatment outcome",

author = "Tarja M{\"a}lk{\"o}nen and Pauliina Nuutinen and Taru Hallinen and Erkki Soini and Riikka Nissinen and Christina Wennerstr{\"o}m and Tapio Rantanen and Hagman, {Johanna H.} and Rauno Harvima and Johanna H{\"o}{\"o}k-Nikanne and Tiina Ilves and P{\"a}ivi Lintu and Ken Malanin and Iina Soram{\"a}ki and Kaisa Tasanen and Arja Teho and Katja V{\"a}h{\"a}vihu and Sari It{\"a}linna and Pekka Leinonen and Piia Saraj{\"a}rvi and Laura Huilaja and Rafael Pasternack",

year = "2022",

doi = "10.2340/actadv.v101.910",

language = "English",

volume = "102",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

publisher = "Medical Journals Sweden",

}

Mälkönen, T, Nuutinen, P, Hallinen, T, Soini, E, Nissinen, R, Wennerström, C, Rantanen, T, Hagman, JH, Harvima, R, Höök-Nikanne, J, Ilves, T, Lintu, P, Malanin, K, Soramäki, I, Tasanen, K, Teho, A, Vähävihu, K, Itälinna, S, Leinonen, P, Sarajärvi, P, Huilaja, L & Pasternack, R 2022, 'Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis', Acta Dermato-Venereologica, vol. 102, adv00631. https://doi.org/10.2340/actadv.v101.910

TY - JOUR

T1 - Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

AU - Mälkönen, Tarja

AU - Nuutinen, Pauliina

AU - Hallinen, Taru

AU - Soini, Erkki

AU - Nissinen, Riikka

AU - Wennerström, Christina

AU - Rantanen, Tapio

AU - Hagman, Johanna H.

AU - Harvima, Rauno

AU - Höök-Nikanne, Johanna

AU - Ilves, Tiina

AU - Lintu, Päivi

AU - Malanin, Ken

AU - Soramäki, Iina

AU - Tasanen, Kaisa

AU - Teho, Arja

AU - Vähävihu, Katja

AU - Itälinna, Sari

AU - Leinonen, Pekka

AU - Sarajärvi, Piia

AU - Huilaja, Laura

AU - Pasternack, Rafael

PY - 2022

Y1 - 2022

N2 - Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.

AB - Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.

KW - Guselkumab

KW - Persistence

KW - Psoriasis

KW - Realworld

KW - Treatment outcome

U2 - 10.2340/actadv.v101.910

DO - 10.2340/actadv.v101.910

M3 - Article

C2 - 34904684

AN - SCOPUS:85123101392

SN - 0001-5555

VL - 102

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

M1 - adv00631

ER -

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Abstract

Funding

Keywords

Publication forum classification

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this